J
Jose M. Gatell
Researcher at University of Barcelona
Publications - 26
Citations - 9621
Jose M. Gatell is an academic researcher from University of Barcelona. The author has contributed to research in topics: Viral load & Acquired immunodeficiency syndrome (AIDS). The author has an hindex of 25, co-authored 26 publications receiving 9412 citations. Previous affiliations of Jose M. Gatell include University of Paris & Imperial College London.
Papers
More filters
Journal ArticleDOI
Antiretroviral Therapy in Adults: Updated Recommendations of the International AIDS Society–USA Panel
Charles C. J. Carpenter,David A. Cooper,Margaret A. Fischl,Jose M. Gatell,Brian Gazzard,Scott M. Hammer,Martin S. Hirsch,Donna M. Jacobsen,David Katzenstein,Julio S. G. Montaner,Douglas D. Richman,Michael S. Saag,Mauro Schechter,Robert T. Schooley,Melanie A. Thompson,Stefano Vella,Patrick Yeni,Paul A. Volberding +17 more
TL;DR: The availability of new antiretroviral drugs has expanded treatment choices and the importance of adherence, emerging long-term complications of therapy, recognition and management of antireTroviral failure, and new monitoring tools are addressed.
Journal ArticleDOI
Treatment for adult HIV infection : 2006 recommendations of the international AIDS society-USA panel
Scott M. Hammer,Michael S. Saag,Mauro Schechter,Julio S. G. Montaner,Robert T. Schooley,Donna M. Jacobsen,Melanie A. Thompson,Charles C. J. Carpenter,Margaret A. Fischl,Brian Gazzard,Jose M. Gatell,Martin S. Hirsch,David Katzenstein +12 more
TL;DR: The virologic target for patients with treatment failure is now a plasma HIV-1 RNA level below 50 copies/mL, making delivery of state-of-the-art care challenging.
Journal ArticleDOI
Antiretroviral Treatment for Adult HIV Infection in 2002: Updated Recommendations of the International AIDS Society-USA Panel
Patrick Yeni,Scott M. Hammer,Charles C. J. Carpenter,David A. Cooper,Margaret A. Fischl,Jose M. Gatell,Brian Gazzard,Martin S. Hirsch,Donna M. Jacobsen,David Katzenstein,Julio S. G. Montaner,Douglas D. Richman,Michael S. Saag,Mauro Schechter,Robert T. Schooley,Melanie A. Thompson,Stefano Vella,Paul A. Volberding +17 more
TL;DR: Because of increased awareness of the activity and toxicity of current drugs, the threshold for initiation of therapy has shifted to a later time in the course of HIV disease, however, the optimal time to initiate therapy remains imprecisely defined.
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel.
Scott M. Hammer,Michael S. Saag,Mauro Schechter,Julio S. G. Montaner,Robert T. Schooley,Donna M. Jacobsen,Melanie A. Thompson,Charles C. J. Carpenter,Margaret A. Fischl,Brian Gazzard,Jose M. Gatell,Martin S. Hirsch,David Katzenstein,Douglas D. Richman,Stefano Vella,Patrick Yeni,Paul A. Volberding +16 more
TL;DR: The virologic target for patients with treatment failure is now a plasma HIV-1 RNA level below 50 copies/mL, making delivery of state-of-the-art care challenging.
Journal ArticleDOI
Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection
Roy T. Steigbigel,David A. Cooper,Princy Kumar,Joseph E. Eron,Mauro Schechter,Martin Markowitz,Mona R. Loutfy,Jeffrey L. Lennox,Jose M. Gatell,Jürgen K. Rockstroh,Christine Katlama,Patrick Yeni,Adriano Lazzarin,Bonaventura Clotet,Jing Zhao,Joshua Chen,Desmond Ryan,Rand R. Rhodes,John A. Killar,Lucinda R. Gilde,Kim M. Strohmaier,Anne R. Meibohm,Michael D. Miller,Daria J. Hazuda,Michael L. Nessly,Mark J. DiNubile,Robin Isaacs,Bach-Yen Nguyen,Hedy Teppler +28 more
TL;DR: In HIV-infected patients with limited treatment options, raltegravir plus optimization background therapy provided better viral suppression than optimized background therapy alone for at least 48 weeks.